Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on Apr 29, 2022 2:50pm
156 Views
Post# 34643269

SQI in good company with Quidel.

SQI in good company with Quidel. SQI has yet to informed stakeholders as to the significance of this partnership.  
During Calendar Q1, SQI acquired the rights to the FIA Sofia 2 Analyzer for Canada.  

SQI to distribute QUIDEL Sofia2 RAPID Antigen Test

The first and Only Health Canada SARS COVID19 RAPID Antigen Test Approved for Asymptomatic Testing

  • Makes this test ideal for employers, educators, governments screening of people with no COVID symptoms

So with a quarter of longterm care homes in Ontario currently experiencing Covid-19 outbreaks, ARE WE offering these tests to these facilities??  What good is it testing asymptomatic visitors with the other rapid tests when they are really only good in the presence of symptoms?  

Someone help me here.....Why is this obvious and important asset not being talked about or shared in a significant way.  People are dying unnecessarily in these facilities.  Please tell us the company is engaged and helping these facilities in great need.  The size of the opportunity is significant too.   

Seeking AlphaQuidel: A Long-Term Revenue Growth StoryQuidel's revenue will grow at a CAGR of high-single-digits in the next five years. · The company's Sofia, Sofia 2, and Triage MeterPro products....1 week ago
<< Previous
Bullboard Posts
Next >>